Literature DB >> 19863574

A comparison of prognostic classification systems for differentiated thyroid carcinoma.

Frederik A Verburg1, Uwe Mäder, Cas L J J Kruitwagen, Markus Luster, Christoph Reiners.   

Abstract

OBJECTIVE: To identify and compare prognostic classification systems based on basic tumour characteristics that were developed and/or validated for differentiated thyroid carcinoma (DTC).
DESIGN: Retrospective chart study.
METHODS: Literature was studied using PubMed. Fifteen different prognostic classification systems were identified, of which seven were developed or validated for DTC patients and were based on basic tumour characteristics. These systems were applied to 1225 DTC patients who were treated in our hospital between 1978 and 2002.
RESULTS: Log-rank analysis of Kaplan-Meier cancer-specific survival curves showed that the curve of the Tumor, Lymph-Node, Metastasis (TNM) system had the greatest discriminatory power (log-rank test, log P = -84.9). Cox-regression analysis showed that the TNM system was the most powerful determinant of cancer-specific survival curves. Proportion of variance explained (PVE) analysis showed that the TNM system had the highest PVE.
CONCLUSION: Of the prognostic classification systems analysed in this study, the TNM system performs best in all the three analyses, and is therefore the most suitable for predicting outcome in DTC-patients.

Entities:  

Mesh:

Year:  2009        PMID: 19863574     DOI: 10.1111/j.1365-2265.2009.03734.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

1.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

2.  Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer.

Authors:  Daniel Mankarios; Peter Baade; Pip Youl; Robin H Mortimer; Adedayo A Onitilo; Anthony Russell; Suhail A R Doi
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

3.  Continuous re-evaluation in differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Christoph Reiners
Journal:  Nat Rev Endocrinol       Date:  2011-01-25       Impact factor: 43.330

4.  Thyroid gland: thyroid surgery and radioiodine ablation-the surgeon's role.

Authors:  Markus Luster; Thomas J Musholt
Journal:  Nat Rev Endocrinol       Date:  2012-11-27       Impact factor: 43.330

5.  Thyroid gland: Can a nomogram predict death in patients with thyroid cancer?

Authors:  Tracy S Wang; Julie A Sosa
Journal:  Nat Rev Endocrinol       Date:  2013-03-05       Impact factor: 43.330

Review 6.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

Review 7.  Multi-targeted approach in the treatment of thyroid cancer.

Authors:  B Zarebczan; H Chen
Journal:  Minerva Chir       Date:  2010-02       Impact factor: 1.000

8.  Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancer.

Authors:  Frederik A Verburg; Uwe Mäder; Markus Luster; Heribert Hänscheid; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-13       Impact factor: 9.236

Review 9.  Prognostic biomarkers in thyroid cancer.

Authors:  Paula Soares; Ricardo Celestino; Miguel Melo; Elsa Fonseca; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

Review 10.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.